Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action

[1]  H. Katus,et al.  Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  J. Hancox,et al.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.

[3]  J. Mitcheson.  Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamine , 2003, British journal of pharmacology.

[4]  H. Katus,et al.  Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  Hugo A Katus,et al.  The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.

[6]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[7]  Stanley Nattel,et al.  A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? , 2002, The Journal of physiology.

[8]  A. Brown,et al.  High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. , 2001, The Journal of pharmacology and experimental therapeutics.

[9]  C R Benedict,et al.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Raimondi,et al.  Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.

[12]  J. Rowe.  Treatment of acute myelogenous leukemia in older adults , 2000, Leukemia.

[13]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[14]  S. Viskin.  Long QT syndromes and torsade de pointes , 1999, The Lancet.

[15]  J. Hancox,et al.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline , 1999, British journal of pharmacology.

[16]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[17]  W. Kübler,et al.  Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[18]  T. Lister,et al.  Treatment of acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[20]  J. Chant,et al.  GTPase cascades choreographing cellular behavior: Movement, morphogenesis, and more , 1995, Cell.

[21]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Seymour.  Induction of hypomagnesemia during amsacrine treatment , 1993, American journal of hematology.

[23]  P. Brons,et al.  Plasma and cellular pharmacokinetics of m‐AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU‐GM, CFU‐L) , 1993, European journal of haematology.

[24]  V. Heinemann,et al.  New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. , 1991, Anticancer research.

[25]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[26]  T. Stijnen,et al.  Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. , 1989, European journal of cancer & clinical oncology.

[27]  S. Marsoni,et al.  Amsacrine-associated cardiotoxicity: an analysis of 82 cases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Foote,et al.  The binding of amsacrine to human plasma proteins , 1986, The Journal of pharmacy and pharmacology.

[29]  J. Griffin,et al.  Amsacrine in refractory acute leukemia. , 1985, Cancer treatment reports.

[30]  C. Presant,et al.  Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. , 1985, Cancer treatment reports.

[31]  Y. Hasin,et al.  Acute electrocardiographic changes induced by amsacrine. , 1984, Cancer treatment reports.

[32]  C. Civin,et al.  QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. , 1984, Cancer treatment reports.

[33]  P. Mclaughlin,et al.  Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia , 1983, Cancer.

[34]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[35]  J. S. Stevenson.  In older adults , 1980 .

[36]  C. Coltman,et al.  Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA). , 1980, Cancer treatment reports.

[37]  T. Lister,et al.  Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside , 2004, Cancer Chemotherapy and Pharmacology.

[38]  J. Paxton,et al.  Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[39]  E. Estey,et al.  New chemotherapeutic agents in acute myeloid leukemia. , 1996, Leukemia.